We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Initiator of Colon Cancer Metastasis Identified

By LabMedica International staff writers
Posted on 29 Sep 2011
A recent study highlighted the role of the BVES (blood vessel epicardial substance) protein in the epithelial-mesenchymal transition (EMT) that occurs when the cells comprising a primary tumor begin to spread and metastasize. More...


The acquisition of a mesenchymal phenotype is a critical step in the metastatic progression of epithelial cancers. Adherens junctions (AJs) are required for suppressing EMT but less is known about the role of tight junctions (TJs) in this process. To elucidate further the factors that drive EMT, investigators at Vanderbilt University (Nashville, TN, USA) examined the function of BVES (also known as POPDC1 and POP1) in relation to the initiation of EMT.

BVES is a highly conserved, transmembrane protein that is involved in cell adhesion, cell motility, and most recently has been shown to play a role in vesicular transport. BVES is found in a wide variety of organisms (from flies to humans) and is a member of the evolutionarily conserved Popdc family of proteins. Although the precise molecular function of BVES is unknown, disruption of this protein results in a wide range of developmental defects and impaired cellular processes.

The investigators reported in the September 12, 2011, online edition of the Journal of Clinical Investigation that they had found that BVES was underexpressed in all stages of human colorectal carcinoma (CRC) and in adenomatous polyps, indicating that its suppression occurred early in transformation. At the genomic level, they found that the BVES promoter was heavily methylated, which silenced its expression. Treating cells that were undergoing EMT with a demethylating agent (the drug decitabine, which is currently used to treat myelodysplastic disorders) restored BVES expression. Renewed BVES expression caused the cells to become more epithelial in nature, and their prometastatic characteristics diminished.

“In cancer, typically the primary tumor does not kill you; it is the metastatic disease that proves lethal," said first author Dr. Christopher Williams, assistant professor of medicine and cancer biology at Vanderbilt University. “So, if targeting BVES could interfere with metastasis; that would be very exciting.”

Related Links:

Vanderbilt University



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
Image: (A) Normal skin and (B) possible pathology in ALS skin (Photo courtesy of Biomolecules and Biomedicine (2025) DOI: 10.17305/bb.2025.12100)

Skin-Based Biomarkers to Enable Early Diagnosis of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that damages motor neurons in the brain and spinal cord, causing muscle weakness, paralysis, and death within three to five... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.